Financial impact of centralized purchasing of rituximab by the Brazilian Ministry of Health for lymphoma treatment, 2015-2022: an exploratory study
We estimated that by taking on the burden of centralized rituximab purchasing, the federal government achieved savings of BRL 81.6 million compared to the hypothetical scenario of rituximab purchasing by oncology hospitals. In addition to the economic benefit, the model ensured the population's access to rituximab and avoided health institution indebtedness.
Authors
- Renato Rocha Martins (ORCID: https://orcid.org/0000-0001-7471-9753)
- Ana Laura de Sene Amâncio Zara (ORCID: https://orcid.org/0000-0001-7012-9078)
- Adriane Lopes Medeiros Simone (ORCID: https://orcid.org/0000-0002-2045-1146)
- Daniela Oliveira de Melo
Institutions
- Universidade Federal de Goiás (BR)
- Universidade Federal de São Paulo (BR)
Publication Details
- Journal
- Epidemiologia e Serviços de Saúde
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1590/s2237-96222025v34e20240203.en
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25